Skip to main content

Table 2 Demographic and clinical characteristics of early and advanced-stages NSCLC patients in TCGA database cohort

From: miR-7 methylation as a biomarker to predict poor survival in early-stage non-small cell lung cancer patients

 

N = 914

Methylated

Unmethylated

p-value

TCGA cohort: early-stage

 

Sex

 Female

372

295 (79%)

77 (21%)

< 0.01

 Male

542

307 (57%)

235 (43%)

Smoking status

 Current smoker

809

510 (63%)

299 (37%)

< 0.01

 Never smoker

83

77 (93%)

6 (7%)

 n.a.

22

  

Tumor histologic type

 Adenocarcinoma

446

423 (95%)

23 (5%)

< 0.01

 Squamous

468

179 (38%)

289 (62%)

Stage

 IA

221

156 (71%)

65 (29%)

< 0.045

 IB

278

187 (67%)

91 (33%)

 IIA

113

63 (56%)

50 (44%)

 IIB

160

98 (61%)

62 (39%)

 IIIA

130

90 (69%)

40 (31%)

 n.a.

12

  
 

N = 55

Methylated

Unmethylated

p-value

TCGA cohort: advanced-stage

Sex

 Female

17

15 (88%)

2 (12%)

0.12

 Male

38

26 (68%)

12 (32%)

Smoking status

 Current smoker

45

32 (70%)

13 (30%)

0.10

 Never smoker

7

0 (0%)

7 (100%)

 n.a.

3

  

Tumor histologic type

 Adenocarcinoma

29

27 (93%)

2 (7%)

0.01

 Squamous

26

14 (54%)

12 (46%)

Stage

 IIIB

26

17 (65%)

9 (35%)

0.14

 IV

29

24 (83%)

5 (17%)

  1. MiR-7 methylation related to gender, smoking status, tumor histologic type, stage and RECIST
  2. n.a. result not available in TCGA cohort